BIIB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Biogen Inc (BIIB) is not a strong buy for a beginner, long-term investor at this moment. While the company has potential long-term catalysts in its pipeline, the current financial performance, insider selling trends, and lack of strong technical or proprietary trading signals suggest that waiting for more clarity on revenue growth and stabilization would be prudent.
The stock's MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 37.402, and the price is near the support level of 187.77. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the overall trend lacks strong upward momentum.
Analysts have raised price targets recently, with some highlighting strong cash flows, improved expense discipline, and potential long-term growth from pipeline drugs like high-dose Spinraza and litifilimab. RBC Capital and Guggenheim see upcoming milestones as potential catalysts.
Insider selling has increased significantly (864.10% over the last month), indicating a lack of confidence from insiders. The company's Q4 2025 financials showed a significant decline in revenue (-7.14% YoY), net income (-118.34% YoY), and EPS (-118.03% YoY). Hedge funds are neutral, and there is no recent news or congress trading data to provide additional support.
In Q4 2025, Biogen's revenue dropped to $2.28 billion (-7.14% YoY), net income fell to -$48.9 million (-118.34% YoY), and EPS decreased to -$0.33 (-118.03% YoY). Gross margin remained stable at 72.46% (-0.08% YoY), but overall financials indicate a challenging period.
Analysts are mixed, with ratings ranging from Neutral to Outperform. Recent price target increases (e.g., RBC to $233, Guggenheim to $246) reflect optimism about long-term catalysts, but concerns about revenue growth persist. Barclays remains cautious with an Equal Weight rating and a $185 price target.
